Navigation
Home
Advocating for Access
Background
Letters for Access
Press Releases For Access
Simplified Community Materials
Simplified Community Materials
Understanding your HCV infection
Community Led Reports
Country Information
Indonesia
India
Vietnam
Generic DAAs Pricing
Resources
Guidelines
Key Research Publication
Other Important Documents and Reports
News
Gallery
Photos
Video
Stories
Response from CEO, CHAI about the Quick Start program in November 2016
Response from CEO, CHAI about the Quick Start program in November 2016
Please click here
December 21, 2016
/
News
Share
the Post
Related
Posts
BMS’ patent bid for Hep C treatment Daclatasvir Challenged
Hepatitis C Treatment Snapshots: ledipasvir and sofosbuvir co-formulation
Asia-Pacific Aids Groups Express Deep Dismay At Conclusion Of Secretly Negotiated Trans-Pacific Partnership Agreement That Threatens Future Access To Affordable Generic Medicines And Sustainable Development Goals
Letter from Community in Asia and Eastern Europe to Global Fund Board for Financing Hep C Treatment
Availability and Pricing of Generic Sofosbuvir in India – Updated 10 September 2015
Glecaprevir-Pibrentasvir Effective for Hepatitis C After Treatment Failure
Part 1: What is hepatitis C and how is it diagnosed?
Read More
Story from Ajitshwor Wangkheirakpam, Manipur, India
